BNP Paribas Financial Markets
CNTA

BNP Paribas Financial Markets’s Centessa Pharmaceuticals CNTA Stock Holding History

BNP Paribas Financial Markets’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.6K Buy
2,482
+36
+1% +$921 ﹤0.01% 4384
2025
Q4 		$61.2K Buy
2,446
+1,248
+104% +$31.6K ﹤0.01% 4588
2025
Q3 		$29.1K Sell
1,198
-33,774
-97% -$600K ﹤0.01% 4809
2025
Q2 		$460K Buy
34,972
+33,854
+3,028% +$429K ﹤0.01% 3374
2025
Q1 		$16.1K Sell
1,118
-8,554
-88% -$140K ﹤0.01% 4595
2024
Q4 		$162K Buy
+9,672
New +$160K ﹤0.01% 3977

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BNP Paribas Financial Markets's CNTA Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Centessa Pharmaceuticals (CNTA) stake by 1.5% in Q1 2026, buying an estimated $921 and bringing the position to 2,482 shares worth $98.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4384.

BNP Paribas Financial Markets first reported a position in CNTA in Q4 2024 and has held it in 6 quarters since. The position peaked at $460K in Q2 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • BNP Paribas Financial Markets held 2,482 shares of Centessa Pharmaceuticals worth $98.6K as of Q1 2026.
  • BNP Paribas Financial Markets bought 36 Centessa Pharmaceuticals shares in Q1 2026, an estimated $921.
  • Centessa Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4384 holding.
  • BNP Paribas Financial Markets first reported a position in Centessa Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Centessa Pharmaceuticals position peaked at $460K in Q2 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.